ATARA BIOTHERAPEUTICS, INC. Amortization of Debt Issuance Costs
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Amortization of Debt Issuance Costs of $30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $17.00K, a 13.33% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $13.00K, a 7.14% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $14.00K, a 6.67% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $15.00K, a 16.67% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2025 was $58.00K, a 13.43% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2024 was $67.00K, a 15.19% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2023 was $79.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $30.00K 10-Q · filed 2026-08-12 | $44.00K derived: sum of 3 quarters · filed 2026-08-12 | $59.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-12 | $27.00K derived: sum of 2 quarters · filed 2026-05-12 | $42.00K derived: sum of 3 quarters · filed 2026-05-12 | $57.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.00K derived: sum of 2 quarters · filed 2026-03-16 | $44.00K derived: sum of 3 quarters · filed 2026-03-16 | $58.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $30.00K derived: sum of 2 quarters · filed 2025-11-12 | $44.00K 10-Q · filed 2025-11-12 | $59.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $29.00K 10-Q · filed 2025-08-11 | $44.00K derived: sum of 3 quarters · filed 2025-08-11 | $62.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | $14.00K 10-Q · filed 2025-05-15 | $29.00K derived: sum of 2 quarters · filed 2025-05-15 | $47.00K derived: sum of 3 quarters · filed 2025-05-15 | $64.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $33.00K derived: sum of 2 quarters · filed 2025-03-07 | $50.00K derived: sum of 3 quarters · filed 2025-03-07 | $67.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $35.00K derived: sum of 2 quarters · filed 2024-11-12 | $52.00K 10-Q · filed 2024-11-12 | $70.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $34.00K 10-Q · filed 2024-08-12 | $52.00K derived: sum of 3 quarters · filed 2024-08-12 | $73.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | $17.00K 10-Q · filed 2024-05-09 | $35.00K derived: sum of 2 quarters · filed 2024-05-09 | $56.00K derived: sum of 3 quarters · filed 2024-05-09 | $76.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $39.00K derived: sum of 2 quarters · filed 2024-03-28 | $59.00K derived: sum of 3 quarters · filed 2024-03-28 | $79.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $41.00K derived: sum of 2 quarters · filed 2023-11-01 | $61.00K 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $40.00K 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $20.00K 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |